New Mexico 2025 Regular Session

New Mexico Senate Bill SB219 Compare Versions

Version 1 (Old)

Version 2 (New)

Old	New		Differences
1		-	~~SJC/SB 219~~
2		-	~~Page 1~~
	1	+	underscored material = new
	2	+	[bracketed material] = delete
3	3		1
4	4		2
5	5		3
6	6		4
7	7		5
8	8		6
9	9		7
10	10		8
11	11		9
12	12		10
13	13		11
14	14		12
15	15		13
16	16		14
17	17		15
18	18		16
19	19		17
20	20		18
21	21		19
22	22		20
23	23		21
24	24		22
25	25		23
26	26		24
27	27		25
	28	+	SENATE BILL 219
	29	+	57
	30	+	TH LEGISLATURE
	31	+	-
	32	+
	33	+	STATE
	34	+
	35	+	OF
	36	+
	37	+	NEW
	38	+
	39	+	MEXICO
	40	+
	41	+	-
	42	+	FIRST SESSION
	43	+	,
	44	+
	45	+	2025
	46	+	INTRODUCED BY
	47	+	Jeff Steinborn and Martin Hickey and Elizabeth "Liz" Thomson
	48	+	and Craig W. Brandt and Andrea Romero
28	49		AN ACT
29	50		RELATING TO HEALTH CARE; ENACTING THE MEDICAL PSILOCYBIN ACT;
30		-	ALLOWING THE USE OF PSILOCYBIN IN AN APPROVED SETTING TO
31		-	~~TREAT~~ QUALIFIED MEDICAL CONDITIONS; CREATING AN ADVISORY
32		-	~~BOARD;~~ PROVIDING POWERS AND DUTIES; AMENDING THE CONTROLLED
33		-	~~SUBSTANCES~~ ACT TO REMOVE PSILOCYBIN AND PSILOCIN FROM THE
34		-	~~SCHEDULE FOR~~ PURPOSES OF QUALIFIED MEDICAL TREATMENT;
35		-	~~PROVIDING A GROSS~~ RECEIPTS TAX DEDUCTION FOR MEDICAL
36		-	~~PSILOCYBIN~~; ~~PRESCRIBING A PENALTY~~.
	51	+	ALLOWING THE USE OF PSILOCYBIN IN AN APPROVED SETTING TO TREAT
	52	+	QUALIFIED MEDICAL CONDITIONS; CREATING AN ADVISORY BOARD;
	53	+	PROVIDING POWERS AND DUTIES; AMENDING THE CONTROLLED SUBSTANCES
	54	+	ACT TO REMOVE PSILOCYBIN AND PSILOCIN FROM THE SCHEDULE FOR
	55	+	PURPOSES OF QUALIFIED MEDICAL TREATMENT; PROVIDING A GROSS
	56	+	RECEIPTS TAX DEDUCTION FOR MEDICAL PSILOCYBIN; PRESCRIBING A
	57	+	PENALTY; MAKING APPROPRIATIONS.
37	58		BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF NEW MEXICO:
38		-	SECTION 1. SHORT TITLE.--Sections 1 through 11 of this
39		-	act may be cited as the "Medical Psilocybin Act".
40		-	SECTION 2. PURPOSE OF ACT.--The purpose of the Medical
41		-	Psilocybin Act is to allow the beneficial use of psilocybin
42		-	in a regulated system for alleviating qualified medical
43		-	conditions.
44		-	SECTION 3. DEFINITIONS.--As used in the Medical
45		-	Psilocybin Act:
46		-	A. "board" means the medical psilocybin advisory
47		-	board;
48		-	B. "clinician" means an approved health care
49		-	provider licensed in New Mexico who holds a permit from the
50		-	department to provide medical services to qualified patients;
51		-	C. "department" means the department of health; SJC/SB 219
52		-	Page 2
	59	+	SECTION 1. [NEW MATERIAL] SHORT TITLE.--Sections 1
	60	+	through 11 of this act may be cited as the "Medical Psilocybin
	61	+	Act".
	62	+	SECTION 2. [NEW MATERIAL] PURPOSE OF ACT.--The purpose of
	63	+	the Medical Psilocybin Act is to allow the beneficial use of
	64	+	.228967B.3 underscored material = new
	65	+	[bracketed material] = delete
53	66		1
54	67		2
55	68		3
56	69		4
57	70		5
58	71		6
59	72		7
60	73		8
61	74		9
62	75		10
63	76		11
64	77		12
65	78		13
66	79		14
67	80		15
68	81		16
69	82		17
70	83		18
71	84		19
72	85		20
73	86		21
74	87		22
75	88		23
76	89		24
77	90		25
78		-	D. "medical services" means services provided to
79		-	a patient in an approved setting before, during and after the
80		-	ingestion of psilocybin and includes a preparation session,
81		-	an administration session and an integration session;
	91	+	psilocybin in a regulated system for alleviating qualified
	92	+	medical conditions.
	93	+	SECTION 3. [NEW MATERIAL] DEFINITIONS.--As used in the
	94	+	Medical Psilocybin Act:
	95	+	A. "board" means the medical psilocybin advisory
	96	+	board;
	97	+	B. "clinician" means an approved health care
	98	+	provider licensed in New Mexico who holds a permit from the
	99	+	department to provide medical services to qualified patients;
	100	+	C. "department" means the department of health;
	101	+	D. "medical services" means services provided to a
	102	+	patient in an approved setting before, during and after the
	103	+	ingestion of psilocybin and includes a preparation session, an
	104	+	administration session and an integration session;
82	105		E. "producer" means a person who has a permit from
83	106		the department to grow and harvest or prepare psilocybin from
84		-	psilocybin-producing mushrooms, including to compound,
85		-	~~convert,~~ process or manufacture psilocybin products directly
86		-	or indirectly from psilocybin mushrooms and to package or
	107	+	psilocybin-producing mushrooms, including to compound, convert,
	108	+	process or manufacture psilocybin products directly or
	109	+	indirectly from psilocybin mushrooms and to package or
87	110		repackage or label or relabel the products;
88	111		F. "program" means the medical use of psilocybin
89	112		program;
90	113		G. "psilocybin" means the naturally occurring
91	114		psychedelic compound 4-phosphoryloxy-N,N-dimethyltryptamine,
92	115		also known as 4-PO-DMT, and its pharmacologically active
93		-	metabolite psilocin, 4-hydroxy-N,N-dimethyltryptamine, found
94		-	in certain mushrooms, but does not include synthetic or
95		-	synthetic analogs of psilocybin;
96		-	H. "qualified patient" means a patient whose
97		-	clinician has judged the patient to be a medically
98		-	appropriate candidate for the use of medical psilocybin based
99		-	on being diagnosed with a qualifying condition;
100		-	I. "qualifying condition" includes:
101		-	(1) major treatment-resistant depression;
102		-	(2) posttraumatic stress disorder; SJC/SB 219
103		-	Page 3
	116	+	.228967B.3
	117	+	- 2 - underscored material = new
	118	+	[bracketed material] = delete
104	119		1
105	120		2
106	121		3
107	122		4
108	123		5
109	124		6
110	125		7
111	126		8
112	127		9
113	128		10
114	129		11
115	130		12
116	131		13
117	132		14
118	133		15
119	134		16
120	135		17
121	136		18
122	137		19
123	138		20
124	139		21
125	140		22
126	141		23
127	142		24
128	143		25
	144	+	metabolite psilocin, 4-hydroxy-N,N-dimethyltryptamine, found in
	145	+	certain mushrooms, but does not include synthetic or synthetic
	146	+	analogs of psilocybin;
	147	+	H. "qualified patient" means a patient whose
	148	+	clinician has judged the patient to be a medically appropriate
	149	+	candidate for the use of medical psilocybin based on being
	150	+	diagnosed with a qualifying condition;
	151	+	I. "qualifying condition" includes:
	152	+	(1) major treatment-resistant depression;
	153	+	(2) posttraumatic stress disorder;
129	154		(3) substance use disorders;
130	155		(4) end-of-life care; and
131	156		(5) other conditions approved by the
132	157		department; and
133	158		J. "secretary" means the secretary of health.
134		-	SECTION 4. APPLICABILITY.--Federal food ~~and drug~~
135		-	administration-approved products that contain ~~psilocybin~~
136		-	shall be exempt from the Medical Psilocybin Act~~, with the~~
137		-	~~exception that~~ such products ~~shall~~ be ~~authorized for use~~:
	159	+	SECTION 4. [NEW MATERIAL] APPLICABILITY.--Federal food
	160	+	and drug administration-approved products that contain
	161	+	psilocybin shall be exempt from the Medical Psilocybin Act.
	162	+	Such products may be used in New Mexico:
138	163		A. in any research conducted by state research
139	164		universities or health care providers pursuant to grants
140	165		awarded through the medical psilocybin research fund; and
141	166		B. by qualified patients whose treatments may be
142	167		funded through the medical psilocybin treatment equity fund.
143		-	SECTION 5. EXEMPTION FROM CRIMINAL AND CIVIL PENALTIES
144		-	FOR THE MEDICAL USE OF PSILOCYBIN.--
145		-	A. A producer, clinician or qualified patient
146		-	shall not be subject to arrest, prosecution or penalty for
147		-	participating in the program.
148		-	B. The following conduct is lawful and shall not
149		-	constitute grounds for detention, search or arrest of a
150		-	person or for a violation of probation or parole, and
151		-	psilocybin that relates to the conduct is not contraband or
152		-	subject to seizure or forfeiture pursuant to the Controlled
153		-	Substances Act or the Forfeiture Act: SJC/SB 219
154		-	Page 4
	168	+	SECTION 5. [NEW MATERIAL] EXEMPTION FROM CRIMINAL AND
	169	+	.228967B.3
	170	+	- 3 - underscored material = new
	171	+	[bracketed material] = delete
155	172		1
156	173		2
157	174		3
158	175		4
159	176		5
160	177		6
161	178		7
162	179		8
163	180		9
164	181		10
165	182		11
166	183		12
167	184		13
168	185		14
169	186		15
170	187		16
171	188		17
172	189		18
173	190		19
174	191		20
175	192		21
176	193		22
177	194		23
178	195		24
179	196		25
	197	+	CIVIL PENALTIES FOR THE MEDICAL USE OF PSILOCYBIN.--
	198	+	A. A producer, clinician or qualified patient shall
	199	+	not be subject to arrest, prosecution or penalty for
	200	+	participating in the program.
	201	+	B. The following conduct is lawful and shall not
	202	+	constitute grounds for detention, search or arrest of a person
	203	+	or for a violation of probation or parole, and psilocybin that
	204	+	relates to the conduct is not contraband or subject to seizure
	205	+	or forfeiture pursuant to the Controlled Substances Act or the
	206	+	Forfeiture Act:
180	207		(1) a producer or clinician possessing or
181		-	transporting not more than an adequate supply of psilocybin
182		-	~~for~~ medical purposes as defined by department rule; and
	208	+	transporting not more than an adequate supply of psilocybin for
	209	+	medical purposes as defined by department rule; and
183	210		(2) a clinician administering or a qualified
184		-	patient taking psilocybin in an approved setting in
185		-	~~accordance~~ with the Medical Psilocybin Act or rules
186		-	~~promulgated in~~ accordance with that act.
	211	+	patient taking psilocybin in an approved setting in accordance
	212	+	with the Medical Psilocybin Act or rules promulgated in
	213	+	accordance with that act.
187	214		C. A clinician shall not be subject to arrest or
188		-	prosecution or denied any right or ~~privilege for recommending~~
189		-	the program or providing medical ~~services authorized in the~~
190		-	~~Medical Psilocybin Act~~.
	215	+	prosecution, penalized in any manner or denied any right or
	216	+	privilege for recommending the program or providing medical
	217	+	services.
191	218		D. A person shall not be subject to arrest or
192	219		prosecution for a psilocybin-related offense for simply being
193	220		in the presence of the medical use of psilocybin as allowed
194	221		under the provisions of the Medical Psilocybin Act.
195		-	E. The Medical Psilocybin Act does not apply to
196		-	federal food and drug administration-approved clinical
197		-	trials.
198		-	SECTION 6. PROHIBITIONS, RESTRICTIONS AND LIMITATIONS
199		-	ON THE USE OF PSILOCYBIN--CRIMINAL PENALTIES.--
200		-	A. Participation in the program by a producer,
201		-	clinician or qualified patient does not relieve the producer,
202		-	clinician or qualified patient from:
203		-	(1) criminal prosecution or civil penalties
204		-	for activities not authorized in the Medical Psilocybin Act; SJC/SB 219
205		-	Page 5
	222	+	.228967B.3
	223	+	- 4 - underscored material = new
	224	+	[bracketed material] = delete
206	225		1
207	226		2
208	227		3
209	228		4
210	229		5
211	230		6
212	231		7
213	232		8
214	233		9
215	234		10
216	235		11
217	236		12
218	237		13
219	238		14
220	239		15
221	240		16
222	241		17
223	242		18
224	243		19
225	244		20
226	245		21
227	246		22
228	247		23
229	248		24
230	249		25
231		-	or
	250	+	E. The Medical Psilocybin Act does not apply to
	251	+	federal food and drug administration-approved clinical trials.
	252	+	SECTION 6. [NEW MATERIAL] PROHIBITIONS, RESTRICTIONS AND
	253	+	LIMITATIONS ON THE USE OF PSILOCYBIN--CRIMINAL PENALTIES.--
	254	+	A. Participation in the program by a producer,
	255	+	clinician or qualified patient does not relieve the producer,
	256	+	clinician or qualified patient from:
	257	+	(1) criminal prosecution or civil penalties
	258	+	for activities not authorized in the Medical Psilocybin Act; or
232	259		(2) liability for damages or criminal
233		-	prosecution arising out of the operation of a motor vehicle
234		-	if driving while under the influence of psilocybin.
	260	+	prosecution arising out of the operation of a motor vehicle if
	261	+	driving while under the influence of psilocybin.
235	262		B. A person who makes a fraudulent representation
236	263		to a law enforcement officer about the person's participation
237		-	in the program to avoid arrest or prosecution for a
238		-	psilocybin-related offense is guilty of a petty misdemeanor
239		-	and shall be sentenced as provided in Section 31-19-1
240		-	NMSA 1978.
241		-	SECTION 7. DEPARTMENT--PROGRAM.--
	264	+	in the program to avoid arrest or prosecution for a psilocybin-
	265	+	related offense is guilty of a petty misdemeanor and shall be
	266	+	sentenced as provided in Section 31-19-1 NMSA 1978.
	267	+	SECTION 7. [NEW MATERIAL] DEPARTMENT--PROGRAM.--
242	268		A. The "medical use of psilocybin program" is
243	269		created in the department. In developing the program, the
244	270		department shall establish:
245	271		(1) appropriate qualifying conditions for
246		-	qualified patients;
247		-	(2) necessary initial and ongoing training
248		-	for producers and clinicians;
249		-	(3) treatment protocols, including patient
250		-	selection criteria, medical service standards, dosage
251		-	standards and approved settings for administration of
252		-	psilocybin to patients;
253		-	(4) safety protocols for producing
254		-	psilocybin from mushrooms, transporting, storing and handling
255		-	psilocybin and treating patients; SJC/SB 219
256		-	Page 6
	272	+	producers, clinicians and qualified patients;
	273	+	(2) necessary initial and ongoing training for
	274	+	producers and clinicians;
	275	+	.228967B.3
	276	+	- 5 - underscored material = new
	277	+	[bracketed material] = delete
257	278		1
258	279		2
259	280		3
260	281		4
261	282		5
262	283		6
263	284		7
264	285		8
265	286		9
266	287		10
267	288		11
268	289		12
269	290		13
270	291		14
271	292		15
272	293		16
273	294		17
274	295		18
275	296		19
276	297		20
277	298		21
278	299		22
279	300		23
280	301		24
281	302		25
	303	+	(3) treatment protocols, including patient
	304	+	selection criteria, medical service standards, dosage standards
	305	+	and approved settings for administration of psilocybin to
	306	+	patients;
	307	+	(4) safety protocols for producing psilocybin
	308	+	from mushrooms, transporting, storing and handling psilocybin
	309	+	and treating patients;
282	310		(5) other best practices for producers and
283	311		clinicians;
284	312		(6) requirements for data collection to
285		-	evaluate the program and the use of best practices by
286		-	~~producers~~ and clinicians; and
	313	+	evaluate the program and the use of best practices by producers
	314	+	and clinicians; and
287	315		(7) other requirements, restrictions and
288	316		limitations promulgated by the department to ensure an
289	317		efficacious program.
290	318		B. The department shall monitor producers and
291		-	clinicians to ensure compliance with the Medical Psilocybin
292		-	Act and rules promulgated in accordance with that act.
293		-	C. The department shall collaborate with the
294		-	board, state higher education institutions and health care
295		-	providers to collect and analyze data to develop best
296		-	practices, including best settings for administration of
297		-	psilocybin, and, by December 31, 2027, implement the program.
298		-	When developing the program, the department shall engage in
299		-	tribal consultation as provided in the State-Tribal
300		-	Collaboration Act.
301		-	SECTION 8. ADVISORY BOARD CREATED--DUTIES.--
302		-	A. The secretary shall establish the "medical
303		-	psilocybin advisory board", consisting of nine members who
304		-	are knowledgeable about the medical use of psilocybin. At
305		-	least one member shall be an enrolled member of an Indian
306		-	nation, tribe or pueblo located wholly or partially in SJC/SB 219
307		-	Page 7
	319	+	clinicians to ensure compliance with the Medical Psilocybin Act
	320	+	and rules promulgated in accordance with that act.
	321	+	C. The department shall collaborate with the board,
	322	+	state higher education institutions and health care providers
	323	+	to collect and analyze data to develop best practices,
	324	+	including best settings for administration of psilocybin, and,
	325	+	by December 31, 2027, implement the program. When developing
	326	+	the program, the department shall engage in tribal consultation
	327	+	as provided in the State-Tribal Collaboration Act.
	328	+	.228967B.3
	329	+	- 6 - underscored material = new
	330	+	[bracketed material] = delete
308	331		1
309	332		2
310	333		3
311	334		4
312	335		5
313	336		6
314	337		7
315	338		8
316	339		9
317	340		10
318	341		11
319	342		12
320	343		13
321	344		14
322	345		15
323	346		16
324	347		17
325	348		18
326	349		19
327	350		20
328	351		21
329	352		22
330	353		23
331	354		24
332	355		25
333		-	New Mexico; one member shall be licensed to provide
334		-	behavioral health care services in New Mexico; one member
335		-	shall be a mental or behavioral health equity advocate;
336		-	one member shall be a representative of the health care
337		-	authority; and at least one member shall be a veteran of
338		-	the United States armed forces. A majority of the members
339		-	constitutes a quorum, and a quorum of the members present and
340		-	a majority vote are needed to take any action.
	356	+	SECTION 8. [NEW MATERIAL] ADVISORY BOARD CREATED--
	357	+	DUTIES.--
	358	+	A. The secretary shall establish the "medical
	359	+	psilocybin advisory board", consisting of nine members who are
	360	+	knowledgeable about the medical use of psilocybin. At least
	361	+	one member shall be an enrolled member of an Indian nation,
	362	+	tribe or pueblo located wholly or partially in New Mexico; one
	363	+	member shall be a mental or behavioral health equity advocate;
	364	+	and one member shall be a representative of the health care
	365	+	authority. A majority of the members constitutes a quorum, and
	366	+	a quorum of the members present and a majority vote are needed
	367	+	to take any action.
341	368		B. The board shall:
342		-	(1) review and recommend to the department
343		-	for approval medical conditions that may benefit from the
344		-	medical use of psilocybin;
345		-	(2) accept and review petitions to add
346		-	medical conditions to the list of medical conditions that
347		-	qualify for the medical use of psilocybin;
348		-	(3) convene at least twice per year to
349		-	conduct public hearings and to evaluate petitions, which
350		-	shall be maintained as confidential personal health
351		-	information;
	369	+	(1) review and recommend to the department for
	370	+	approval medical conditions that may benefit from the medical
	371	+	use of psilocybin;
	372	+	(2) accept and review petitions to add medical
	373	+	conditions to the list of medical conditions that qualify for
	374	+	the medical use of psilocybin;
	375	+	(3) convene at least twice per year to conduct
	376	+	public hearings and to evaluate petitions, which shall be
	377	+	maintained as confidential personal health information, to add
	378	+	additional medical conditions that qualify for the medical use
	379	+	of psilocybin;
352	380		(4) recommend patient qualifications;
353		-	(5) recommend formulation or preparation
354		-	rules and dosage standards for psilocybin; and
355		-	(6) assist the department in establishing,
356		-	monitoring and evaluating best practices for producers and
357		-	clinicians. SJC/SB 219
358		-	Page 8
	381	+	.228967B.3
	382	+	- 7 - underscored material = new
	383	+	[bracketed material] = delete
359	384		1
360	385		2
361	386		3
362	387		4
363	388		5
364	389		6
365	390		7
366	391		8
367	392		9
368	393		10
369	394		11
370	395		12
371	396		13
372	397		14
373	398		15
374	399		16
375	400		17
376	401		18
377	402		19
378	403		20
379	404		21
380	405		22
381	406		23
382	407		24
383	408		25
384		-	SECTION 9. ASSESSMENT REPORTING.--The department shall
385		-	promulgate rules for the collection of data from producers,
386		-	clinicians and qualified patients as a means to evaluate the
387		-	efficacy of the medical use of psilocybin and publish an
388		-	annual assessment of the program. The assessment shall
389		-	consider the needs of qualified patients who live in rural
390		-	areas, federal subsidized housing or on reservations of
391		-	New Mexico Indian nations, tribes or pueblos, as long as
392		-	the qualified patient's place of residence is wholly within
393		-	the exterior boundaries of the state. Data shall be reported
394		-	in such a way that an individual qualified patient cannot be
	409	+	(5) recommend formulation or preparation rules
	410	+	and dosage standards for psilocybin; and
	411	+	(6) assist the department in establishing,
	412	+	monitoring and evaluating best practices for producers and
	413	+	clinicians.
	414	+	SECTION 9. [NEW MATERIAL] ASSESSMENT REPORTING.--The
	415	+	department shall promulgate rules for the collection of data
	416	+	from producers, clinicians and qualified patients as a means to
	417	+	evaluate the efficacy of the medical use of psilocybin and
	418	+	publish an annual assessment of the program. The assessment
	419	+	shall consider the needs of qualified patients who live in
	420	+	rural areas, federal subsidized housing or on reservations of
	421	+	New Mexico Indian nations, tribes or pueblos, as long as the
	422	+	qualified patient's place of residence is wholly within the
	423	+	exterior boundaries of the state. Data shall be reported in
	424	+	such a way that an individual qualified patient cannot be
395	425		identified.
396		-	SECTION 10. PERSONS UNDER STATE ~~SUPERVISION--~~
397		-	PROTECTIONS.--A person who is serving a period of ~~probation~~
398		-	or parole or who is in the custody or under the ~~supervision~~
399		-	of the state or a local government pending trial as ~~part of a~~
400		-	community supervision program shall not be penalized ~~for~~
401		-	participation in the program.
402		-	SECTION 11. FUNDS--CREATED.--
	426	+	SECTION 10. [NEW MATERIAL] PERSONS UNDER STATE
	427	+	SUPERVISION--PROTECTIONS.--A person who is serving a period of
	428	+	probation or parole or who is in the custody or under the
	429	+	supervision of the state or a local government pending trial as
	430	+	part of a community supervision program shall not be penalized
	431	+	for participation in the program.
	432	+	SECTION 11. [NEW MATERIAL] FUNDS--CREATED.--
403	433		A. The "medical psilocybin treatment equity fund"
404		-	is created as a nonreverting fund in the state treasury. The
405		-	fund consists of appropriations, gifts, grants and donations.
406		-	The fund shall be used to fund treatments of qualified
407		-	patients who meet income requirements determined by rule of
408		-	the department. The department shall administer the fund, SJC/SB 219
409		-	Page 9
	434	+	.228967B.3
	435	+	- 8 - underscored material = new
	436	+	[bracketed material] = delete
410	437		1
411	438		2
412	439		3
413	440		4
414	441		5
415	442		6
416	443		7
417	444		8
418	445		9
419	446		10
420	447		11
421	448		12
422	449		13
423	450		14
424	451		15
425	452		16
426	453		17
427	454		18
428	455		19
429	456		20
430	457		21
431	458		22
432	459		23
433	460		24
434	461		25
435		-	and money in the fund is subject to appropriation by the
	462	+	is created as a nonreverting fund in the state treasury. The
	463	+	fund consists of appropriations, gifts, grants and donations.
	464	+	The fund shall be used to fund treatments of qualified patients
	465	+	who meet income requirements determined by rule of the
	466	+	department. The department shall administer the fund, and
	467	+	money in the fund is subject to appropriation by the
436	468		legislature. Expenditures from the fund shall be by warrants
437	469		signed by the secretary of finance and administration on
438	470		vouchers signed by the secretary of health or the secretary's
439	471		authorized representative.
440	472		B. The "medical psilocybin research fund" is
441		-	created as a nonreverting fund in the state treasury. The
442		-	~~fund~~ consists of appropriations, gifts, grants and donations.
443		-	~~The~~ fund shall be used to provide grants to state research
	473	+	created as a nonreverting fund in the state treasury. The fund
	474	+	consists of appropriations, gifts, grants and donations. The
	475	+	fund shall be used to provide grants to state research
444	476		universities and health care providers that are studying any
445	477		facet of the medical use of psilocybin. The department shall
446	478		administer the fund, and money in the fund is subject to
447	479		appropriation by the legislature. Expenditures from the fund
448	480		shall be by warrants signed by the secretary of finance and
449		-	administration on vouchers signed by the secretary of health
450		-	or the secretary's authorized representative.
451		-	SECTION 12. Section 7-9-73.2 NMSA 1978 (being
452		-	Laws 1998, Chapter 95, Section 2 and Laws 1998, Chapter 99,
453		-	Section 4, as amended) is amended to read:
454		-	"7-9-73.2. DEDUCTION--GROSS RECEIPTS TAX AND
455		-	GOVERNMENTAL GROSS RECEIPTS TAX--PRESCRIPTION DRUGS--OXYGEN--
456		-	CANNABIS--PSILOCYBIN.--
457		-	A. Receipts from the sale of prescription drugs
458		-	and oxygen and oxygen services provided by a licensed
459		-	medicare durable medical equipment provider and cannabis SJC/SB 219
460		-	Page 10
	481	+	administration on vouchers signed by the secretary of health or
	482	+	the secretary's authorized representative.
	483	+	SECTION 12. Section 7-9-73.2 NMSA 1978 (being Laws 1998,
	484	+	Chapter 95, Section 2 and Laws 1998, Chapter 99, Section 4, as
	485	+	amended) is amended to read:
	486	+	"7-9-73.2. DEDUCTION--GROSS RECEIPTS TAX AND GOVERNMENTAL
	487	+	.228967B.3
	488	+	- 9 - underscored material = new
	489	+	[bracketed material] = delete
461	490		1
462	491		2
463	492		3
464	493		4
465	494		5
466	495		6
467	496		7
468	497		8
469	498		9
470	499		10
471	500		11
472	501		12
473	502		13
474	503		14
475	504		15
476	505		16
477	506		17
478	507		18
479	508		19
480	509		20
481	510		21
482	511		22
483	512		23
484	513		24
485	514		25
486		-	products that are sold in accordance with the Lynn and Erin
487		-	Compassionate Use Act and psilocybin products and medical
488		-	care that are sold in accordance with the Medical Psilocybin
489		-	Act may be deducted from gross receipts and governmental
490		-	gross receipts.
	515	+	GROSS RECEIPTS TAX--PRESCRIPTION DRUGS--OXYGEN--CANNABIS--
	516	+	PSILOCYBIN.--
	517	+	A. Receipts from the sale of prescription drugs and
	518	+	oxygen and oxygen services provided by a licensed medicare
	519	+	durable medical equipment provider and cannabis products that
	520	+	are sold in accordance with the Lynn and Erin Compassionate Use
	521	+	Act and psilocybin products and medical care that are sold in
	522	+	accordance with the Medical Psilocybin Act may be deducted from
	523	+	gross receipts and governmental gross receipts.
491	524		B. For the purposes of this section, "prescription
492	525		drugs" means insulin and substances that are:
493		-	(1) dispensed by or under the supervision
494		-	~~of a~~ licensed pharmacist or by a physician or other person
	526	+	(1) dispensed by or under the supervision of a
	527	+	licensed pharmacist or by a physician or other person
495	528		authorized under state law to do so;
496	529		(2) prescribed for a specified person by a
497	530		person authorized under state law to prescribe the substance;
498	531		and
499	532		(3) subject to the restrictions on sale
500		-	contained in Subparagraph 1 of Subsection (b) of 21
501		-	USCA 353."
	533	+	contained in Subparagraph 1 of Subsection (b) of 21 USCA 353."
502	534		SECTION 13. Section 30-31-6 NMSA 1978 (being Laws 1972,
503	535		Chapter 84, Section 6, as amended) is amended to read:
504	536		"30-31-6. SCHEDULE I.--The following controlled
505	537		substances are included in Schedule I:
506	538		A. any of the following opiates, including their
507		-	isomers, esters, ethers, salts and salts of isomers, esters
508		-	and ethers, unless specifically exempted, whenever the
509		-	existence of these isomers, esters, ethers and salts is
510		-	possible within the specific chemical designation: SJC/SB 219
511		-	Page 11
	539	+	isomers, esters, ethers, salts and salts of isomers, esters and
	540	+	.228967B.3
	541	+	- 10 - underscored material = new
	542	+	[bracketed material] = delete
512	543		1
513	544		2
514	545		3
515	546		4
516	547		5
517	548		6
518	549		7
519	550		8
520	551		9
521	552		10
522	553		11
523	554		12
524	555		13
525	556		14
526	557		15
527	558		16
528	559		17
529	560		18
530	561		19
531	562		20
532	563		21
533	564		22
534	565		23
535	566		24
536	567		25
	568	+	ethers, unless specifically exempted, whenever the existence of
	569	+	these isomers, esters, ethers and salts is possible within the
	570	+	specific chemical designation:
537	571		(1) acetylmethadol;
538	572		(2) allylprodine;
539	573		(3) alphacetylmethadol;
540	574		(4) alphameprodine;
541	575		(5) alphamethadol;
542	576		(6) benzethidine;
543	577		(7) betacetylmethadol;
544	578		(8) betameprodine;
545	579		(9) betamethadol;
546	580		(10) betaprodine;
547	581		(11) clonitazene;
548	582		(12) dextromoramide;
549	583		(13) dextrorphan;
550	584		(14) diampromide;
551	585		(15) diethylthiambutene;
552	586		(16) dimenoxadol;
553	587		(17) dimepheptanol;
554	588		(18) dimethylthiambutene;
555	589		(19) dioxaphetyl butyrate;
556	590		(20) dipipanone;
557	591		(21) ethylmethylthiambutene;
558	592		(22) etonitazene;
559		-	(23) etoxeridine;
560		-	(24) furethidine;
561		-	(25) hydroxypethidine; SJC/SB 219
562		-	Page 12
	593	+	.228967B.3
	594	+	- 11 - underscored material = new
	595	+	[bracketed material] = delete
563	596		1
564	597		2
565	598		3
566	599		4
567	600		5
568	601		6
569	602		7
570	603		8
571	604		9
572	605		10
573	606		11
574	607		12
575	608		13
576	609		14
577	610		15
578	611		16
579	612		17
580	613		18
581	614		19
582	615		20
583	616		21
584	617		22
585	618		23
586	619		24
587	620		25
	621	+	(23) etoxeridine;
	622	+	(24) furethidine;
	623	+	(25) hydroxypethidine;
588	624		(26) ketobemidone;
589	625		(27) levomoramide;
590	626		(28) levophenacylmorphan;
591	627		(29) morpheridine;
592	628		(30) noracymethadol;
593	629		(31) norlevorphanol;
594	630		(32) normethadone;
595	631		(33) norpipanone;
596	632		(34) phenadoxone;
597	633		(35) phenampromide;
598	634		(36) phenomorphan;
599	635		(37) phenoperidine;
600	636		(38) piritramide;
601	637		(39) proheptazine;
602	638		(40) properidine;
603	639		(41) racemoramide; and
604	640		(42) trimeperidine;
605	641		B. any of the following opium derivatives, their
606	642		salts, isomers and salts of isomers, unless specifically
607	643		exempted, whenever the existence of these salts, isomers and
608	644		salts of isomers is possible within the specific chemical
609	645		designation:
610		-	(1) acetorphine;
611		-	(2) acetyldihydrocodeine;
612		-	(3) benzylmorphine; SJC/SB 219
613		-	Page 13
	646	+	.228967B.3
	647	+	- 12 - underscored material = new
	648	+	[bracketed material] = delete
614	649		1
615	650		2
616	651		3
617	652		4
618	653		5
619	654		6
620	655		7
621	656		8
622	657		9
623	658		10
624	659		11
625	660		12
626	661		13
627	662		14
628	663		15
629	664		16
630	665		17
631	666		18
632	667		19
633	668		20
634	669		21
635	670		22
636	671		23
637	672		24
638	673		25
	674	+	(1) acetorphine;
	675	+	(2) acetyldihydrocodeine;
	676	+	(3) benzylmorphine;
639	677		(4) codeine methylbromide;
640	678		(5) codeine-N-oxide;
641	679		(6) cyprenorphine;
642	680		(7) desomorphine;
643	681		(8) dihydromorphine;
644	682		(9) etorphine;
645	683		(10) heroin;
646	684		(11) hydromorphinol;
647	685		(12) methyldesorphine;
648	686		(13) methyldihydromorphine;
649	687		(14) morphine methylbromide;
650	688		(15) morphine methylsulfonate;
651	689		(16) morphine-N-oxide;
652	690		(17) myrophine;
653	691		(18) nicocodeine;
654	692		(19) nicomorphine;
655	693		(20) normorphine;
656	694		(21) pholcodine; and
657	695		(22) thebacon;
658	696		C. any material, compound, mixture or preparation
659	697		that contains any quantity of the following hallucinogenic
660	698		substances, their salts, isomers and salts of isomers, unless
661		-	specifically exempted, whenever the existence of these salts,
662		-	isomers and salts of isomers is possible within the specific
663		-	chemical designation: SJC/SB 219
664		-	Page 14
	699	+	.228967B.3
	700	+	- 13 - underscored material = new
	701	+	[bracketed material] = delete
665	702		1
666	703		2
667	704		3
668	705		4
669	706		5
670	707		6
671	708		7
672	709		8
673	710		9
674	711		10
675	712		11
676	713		12
677	714		13
678	715		14
679	716		15
680	717		16
681	718		17
682	719		18
683	720		19
684	721		20
685	722		21
686	723		22
687	724		23
688	725		24
689	726		25
	727	+	specifically exempted, whenever the existence of these salts,
	728	+	isomers and salts of isomers is possible within the specific
	729	+	chemical designation:
690	730		(1) 3,4-methylenedioxy amphetamine;
691		-	(2) 5-methoxy-3,4-methylenedioxy
692		-	amphetamine;
	731	+	(2) 5-methoxy-3,4-methylenedioxy amphetamine;
693	732		(3) 3,4,5-trimethoxy amphetamine;
694	733		(4) bufotenine;
695	734		(5) diethyltryptamine;
696	735		(6) dimethyltryptamine;
697	736		(7) 4-methyl-2,5-dimethoxy amphetamine;
698	737		(8) ibogaine;
699	738		(9) lysergic acid diethylamide;
700	739		(10) mescaline;
701	740		(11) peyote, except as otherwise provided in
702	741		the Controlled Substances Act;
703	742		(12) N-ethyl-3-piperidyl benzilate;
704	743		(13) N-methyl-3-piperidyl benzilate;
705		-	(14) psilocybin, except as provided
	744	+	(14) psilocybin, except as provided otherwise
	745	+	in the Controlled Substances Act and the Medical Psilocybin
	746	+	Act;
	747	+	(15) [psilocyn] psilocin, except as provided
706	748		otherwise in the Controlled Substances Act and the Medical
707	749		Psilocybin Act;
708		-	(15) psilocin, except as provided otherwise
709		-	in the Controlled Substances Act and the Medical Psilocybin
710		-	Act;
711	750		(16) synthetic cannabinoids, including:
712	751		(a) 1-[2-(4-(morpholinyl)ethyl]
713		-	-3~~-(1-naphthoyl)indole;~~
714		-	~~(b) 1-butyl-3-(1-napthoyl)indole; SJC/SB 219~~
715		-	~~Page 15~~
	752	+	.228967B.3
	753	+	- 14 - underscored material = new
	754	+	[bracketed material] = delete
716	755		1
717	756		2
718	757		3
719	758		4
720	759		5
721	760		6
722	761		7
723	762		8
724	763		9
725	764		10
726	765		11
727	766		12
728	767		13
729	768		14
730	769		15
731	770		16
732	771		17
733	772		18
734	773		19
735	774		20
736	775		21
737	776		22
738	777		23
739	778		24
740	779		25
	780	+	-3-(1-naphthoyl)indole;
	781	+	(b) 1-butyl-3-(1-napthoyl)indole;
741	782		(c) 1-hexyl-3-(1-naphthoyl)indole;
742	783		(d) 1-pentyl-3-(1-naphthoyl)indole;
743	784		(e) 1-pentyl-3-(2-methoxyphenylacetyl)
744	785		indole;
745	786		(f) cannabicyclohexanol (CP 47, 497 and
746	787		homologues: 5-(1,1-dimethylheptyl)-2-[(1R,3S)
747	788		-3-hydroxycyclohexyl]-phenol (CP-47,497); and 5-(1,
748	789		1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol;
749	790		(g) 6aR,10aR)-9-(hydroxymethyl)
750	791		-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,
751	792		10a-tetrahydrobenzo[c]chromen-1-ol);
752	793		(h) dexanabinol, (6aS,10aS)
753	794		-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)
754	795		-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol;
755	796		(i) 1-pentyl-3-(4-chloro naphthoyl)
756	797		indole;
757	798		(j) (2-methyl-1-propyl-1H-indol-3-yl)
758	799		-1-naphthalenyl-methanone; and
759	800		(k) 5-(1,1-dimethylheptyl)-2-(3-hydroxy
760	801		cyclohexyl)-phenol;
761	802		(17) 3,4-methylenedioxymethcathinone;
762	803		(18) 3,4-methylenedioxypyrovalerone;
763	804		(19) 4-methylmethcathinone;
764		-	~~(20) 4-methoxymethcathinone;~~
765		-	~~(21) 3-fluoromethcathinone;~~ ~~and SJC/SB 219~~
766		-	~~Page 16~~
	805	+	.228967B.3
	806	+	- 15 - underscored material = new
	807	+	[bracketed material] = delete
767	808		1
768	809		2
769	810		3
770	811		4
771	812		5
772	813		6
773	814		7
774	815		8
775	816		9
776	817		10
777	818		11
778	819		12
779	820		13
780	821		14
781	822		15
782	823		16
783	824		17
784	825		18
785	826		19
786	827		20
787	828		21
788	829		22
789	830		23
790	831		24
791	832		25
	833	+	(20) 4-methoxymethcathinone;
	834	+	(21) 3-fluoromethcathinone; and
792	835		(22) 4-fluoromethcathinone;
793	836		D. the enumeration of peyote as a controlled
794	837		substance does not apply to the use of peyote in bona fide
795		-	religious ceremonies by a bona fide religious organization,
796		-	~~and~~ members of the organization so using peyote are exempt
797		-	~~from~~ registration. Any person who manufactures peyote for or
	838	+	religious ceremonies by a bona fide religious organization, and
	839	+	members of the organization so using peyote are exempt from
	840	+	registration. Any person who manufactures peyote for or
798	841		distributes peyote to the organization or its members shall
799		-	comply with the federal Comprehensive Drug Abuse Prevention
800		-	~~and~~ Control Act of 1970 and all other requirements of law;
	842	+	comply with the federal Comprehensive Drug Abuse Prevention and
	843	+	Control Act of 1970 and all other requirements of law;
801	844		E. the enumeration of psilocybin and psilocin in
802	845		this schedule does not apply to their medical use as provided
803		-	in the Medical Psilocybin Act;
804		-	F. the enumeration of Schedule I controlled
	846	+	in the Medical Psilocybin Act. Any person who is a producer or
	847	+	clinician under that act shall comply with the federal
	848	+	Comprehensive Drug Abuse Prevention and Control Act of 1970 and
	849	+	other requirements of law;
	850	+	[E.] F. the enumeration of Schedule I controlled
805	851		substances does not apply to:
806		-	(1) hemp pursuant to rules promulgated by
807		-	the board of regents of New Mexico state university on behalf
808		-	of the New Mexico department of agriculture;
809		-	(2) cultivation of hemp by persons pursuant
810		-	to rules promulgated by the board of regents of New Mexico
811		-	state university on behalf of the New Mexico department of
812		-	agriculture;
813		-	(3) tetrahydrocannabinols or chemical
814		-	derivatives of tetrahydrocannabinols, including
815		-	tetrahydrocannabinols or chemical derivatives of
816		-	tetrahydrocannabinols with concentrations of up to five SJC/SB 219
817		-	Page 17
	852	+	(1) hemp pursuant to rules promulgated by the
	853	+	board of regents of New Mexico state university on behalf of
	854	+	the New Mexico department of agriculture;
	855	+	(2) cultivation of hemp by persons pursuant to
	856	+	rules promulgated by the board of regents of New Mexico state
	857	+	university on behalf of the New Mexico department of
	858	+	.228967B.3
	859	+	- 16 - underscored material = new
	860	+	[bracketed material] = delete
818	861		1
819	862		2
820	863		3
821	864		4
822	865		5
823	866		6
824	867		7
825	868		8
826	869		9
827	870		10
828	871		11
829	872		12
830	873		13
831	874		14
832	875		15
833	876		16
834	877		17
835	878		18
836	879		19
837	880		20
838	881		21
839	882		22
840	883		23
841	884		24
842	885		25
843		-	percent as measured using a post-decarboxylation method and
844		-	based on percentage dry weight, possessed by a person in
845		-	connection with the cultivation, transportation, testing,
846		-	researching, manufacturing or other processing of the plant
847		-	Cannabis sativa L., or any part of the plant whether growing
848		-	or not, if authorized pursuant to rules promulgated, pursuant
849		-	to the Hemp Manufacturing Act, by the board of regents of
850		-	New Mexico state university on behalf of the New Mexico
851		-	department of agriculture or the department of environment;
852		-	or
	886	+	agriculture;
	887	+	(3) tetrahydrocannabinols or chemical
	888	+	derivatives of tetrahydrocannabinols, including
	889	+	tetrahydrocannabinols or chemical derivatives of
	890	+	tetrahydrocannabinols with concentrations of up to five percent
	891	+	as measured using a post-decarboxylation method and based on
	892	+	percentage dry weight, possessed by a person in connection with
	893	+	the cultivation, transportation, testing, researching,
	894	+	manufacturing or other processing of the plant Cannabis sativa
	895	+	L., or any part of the plant whether growing or not, if
	896	+	authorized pursuant to rules promulgated, pursuant to the Hemp
	897	+	Manufacturing Act, by the board of regents of New Mexico state
	898	+	university on behalf of the New Mexico department of
	899	+	agriculture or the department of environment; or
853	900		(4) tetrahydrocannabinols or chemical
854	901		derivatives of tetrahydrocannabinols, including
855	902		tetrahydrocannabinols or chemical derivatives of
856		-	tetrahydrocannabinols in any concentration possessed by
857		-	a person in connection with the extraction of
	903	+	tetrahydrocannabinols in any concentration possessed by a
	904	+	person in connection with the extraction of
858	905		tetrahydrocannabinols or chemical derivatives of
859	906		tetrahydrocannabinols, if authorized pursuant to rules
860		-	promulgated, pursuant to the Hemp Manufacturing Act, by
861		-	the board of regents of New Mexico state university on behalf
862		-	of the New Mexico department of agriculture or the department
863		-	of environment; and
864		-	G. controlled substances added to Schedule I
865		-	by rule adopted by the board pursuant to Section 30-31-3
866		-	NMSA 1978."
	907	+	promulgated, pursuant to the Hemp Manufacturing Act, by the
	908	+	board of regents of New Mexico state university on behalf of
	909	+	the New Mexico department of agriculture or the department of
	910	+	environment; and
	911	+	.228967B.3
	912	+	- 17 - underscored material = new
	913	+	[bracketed material] = delete
	914	+	1
	915	+	2
	916	+	3
	917	+	4
	918	+	5
	919	+	6
	920	+	7
	921	+	8
	922	+	9
	923	+	10
	924	+	11
	925	+	12
	926	+	13
	927	+	14
	928	+	15
	929	+	16
	930	+	17
	931	+	18
	932	+	19
	933	+	20
	934	+	21
	935	+	22
	936	+	23
	937	+	24
	938	+	25
	939	+	[F.] G. controlled substances added to Schedule I
	940	+	by rule adopted by the board pursuant to Section 30-31-3 NMSA
	941	+	1978."
	942	+	SECTION 14. APPROPRIATIONS.--
	943	+	A. Two million dollars ($2,000,000) is appropriated
	944	+	from the general fund to the department of health for
	945	+	expenditure in fiscal years 2026 and 2027 to carry out the
	946	+	provisions of the Medical Psilocybin Act. Any unexpended or
	947	+	unencumbered balance remaining at the end of fiscal year 2026
	948	+	shall revert to the general fund.
	949	+	B. One million dollars ($1,000,000) is appropriated
	950	+	from the general fund to the medical psilocybin treatment
	951	+	equity fund for expenditure in fiscal year 2026 and subsequent
	952	+	fiscal years to carry out the purposes of the fund. Any
	953	+	unexpended or unencumbered balance remaining at the end of a
	954	+	fiscal year shall not revert to the general fund.
	955	+	C. One million dollars ($1,000,000) is appropriated
	956	+	from the general fund to the medical psilocybin research fund
	957	+	for expenditure in fiscal year 2026 and subsequent fiscal years
	958	+	to carry out the purposes of the fund. Any unexpended or
	959	+	unencumbered balance remaining at the end of a fiscal year
	960	+	shall not revert to the general fund.
	961	+	- 18 -
	962	+	.228967B.3